Report cover image

Subarachnoid Hemorrhage Drug Pipeline Analysis Report 2025

Publisher Expert Market Research
Published May 25, 2025
Length 200 Pages
SKU # EMAR20147057

Description

Subarachnoid hemorrhage (SAH) is a life-threatening condition characterized by bleeding in the space between the brain and its surrounding membranes. It accounts for 3% to 5% of the global cerebrovascular disease burden, affecting around 500,000 individuals annually. The disease often results in significant neurological impairment or death. There is a high unmet clinical need for more effective therapies, as current treatment options, such as surgical intervention and blood pressure management, are limited in addressing long-term outcomes. The growing focus on advanced subarachnoid hemorrhage drugs is expected to support pipeline growth and improve patient prognosis in the coming years.

Report Coverage

The Subarachnoid Hemorrhage Drug Pipeline Insight Report by Expert Market Research gives comprehensive insights into subarachnoid hemorrhage therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for subarachnoid hemorrhage. The subarachnoid hemorrhage report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The subarachnoid hemorrhage pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with subarachnoid hemorrhage treatment guidelines to ensure optimal care practices.

The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to subarachnoid hemorrhage.

Subarachnoid Hemorrhage Drug Pipeline Outlook

Subarachnoid hemorrhage is a life-threatening condition in which bleeding occurs in the space between the brain and the surrounding membrane. It is commonly caused by the rupture of an aneurysm, trauma, or arteriovenous malformations. This hemorrhage leads to increased intracranial pressure and potential brain damage, often resulting in a sudden severe headache, nausea, and loss of consciousness.

Subarachnoid hemorrhage treatments focus on stabilizing the patient, preventing rebleeding, and managing complications. Surgical interventions include clipping or coiling aneurysms. Additionally, blood pressure control, vasospasm management, and neuroprotective therapies are crucial. Antifibrinolytics may be used to prevent rebleeding, while rehabilitation therapies are often necessary for recovery.

Subarachnoid Hemorrhage Epidemiology

Subarachnoid hemorrhage is a critical cerebrovascular condition, comprising 3% to 5% of all cerebrovascular diseases, with an estimated 500,000 new cases globally each year. The incidence in the United Kingdom is approximately 8 per 100,000 individuals, with women being more likely to be affected. In the United States, it occurs in 10 to 14 individuals per 100,000 individuals annually, while a global meta-analysis reports an incidence of 7.9 per 100,000, higher in Asian populations.

Subarachnoid Hemorrhage Drug Pipeline Therapeutic Assessment

This section of the report covers the analysis of subarachnoid hemorrhage drug candidates based on several segmentations, including:

By Phase
  • Late-Stage Products (Phase 3 and Phase 4)
  • Mid-Stage Products (Phase 2)
  • Early-Stage Products (Phase I)
  • Preclinical and Discovery Stage Products
By Drug Class
  • Small Molecules
  • Biologics
  • Gene Therapies
  • Peptides
  • Cell-Based Therapies
By Route of Administration
  • Oral
  • Parenteral
  • Others
Subarachnoid Hemorrhage Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis , phase II covers a major share of the total subarachnoid hemorrhage clinical trials.

Subarachnoid Hemorrhage – Pipeline Assessment Segmentation, By Drug Classes

The drug molecule categories covered under the subarachnoid hemorrhage pipeline analysis include small molecules, biologics, gene therapies, peptides, and cell-based therapies. The report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for subarachnoid hemorrhage.

Subarachnoid Hemorrhage Clinical Trials Therapeutic Assessment – Competitive Dynamics

The EMR report for the subarachnoid hemorrhage report insights includes the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in subarachnoid hemorrhage clinical trials:
  • Acasti Pharma Inc.
  • Cumberland Pharmaceuticals
  • Takeda Pharmaceuticals
  • Orion Corporation
  • Arbor Pharmaceuticals
  • Edge Therapeutics Inc.
Subarachnoid Hemorrhage Emerging Drugs Profile

This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for subarachnoid hemorrhage. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of subarachnoid hemorrhage drug candidates.

Drug: Telavancin Injection

The clinical trial, sponsored by Aaron Cook from the University of Kentucky, aims to evaluate the CNS penetration of telavancin in patients with subarachnoid hemorrhage. This Phase 4 study will examine the drug's cerebrospinal fluid (CSF) concentrations in critically ill patients with external ventricular drains (EVDs). The study is expected to be completed by January 2026, with an estimated 20 participants.

Drug: Levosimendan

The Phase II trial, sponsored by Assistance Publique - Hôpitaux de Paris, is evaluating Levosimendan's impact on delayed cerebral ischemia and cerebral vasospasm in patients with aneurysmal subarachnoid haemorrhage. With around 30 participants, the trial is expected to conclude by January 2025.

Drug: Long Term Prophylactic Antibiotics (Nafcillin or Doxycycline)

Montefiore Medical Center is sponsoring a Phase 1 trial investigating prophylactic antibiotics with antibiotic-impregnated external ventricular drains (EVDs). The study aims to assess ventriculostomy-related infections in subarachnoid hemorrhage and related conditions. It compares 24-hour antibiotic use versus prolonged use. It is expected to enroll about 84 participants, with completion anticipated by June 2026.

Reasons To Buy This Report

The Subarachnoid Hemorrhage Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for subarachnoid hemorrhage. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities within subarachnoid hemorrhage pipeline insights.

Key Questions Answered in the Subarachnoid Hemorrhage – Pipeline Insight Report
  • Which companies/institutions are leading the subarachnoid hemorrhage drug development?
  • What is the efficacy and safety profile of subarachnoid hemorrhage pipeline drugs?
  • Which company is leading the subarachnoid hemorrhage pipeline development activities?
  • What is the current subarachnoid hemorrhage commercial assessment?
  • What are the opportunities and challenges present in the subarachnoid hemorrhage drug pipeline landscape?
  • What is the efficacy and safety profile of subarachnoid hemorrhage pipeline drugs?
  • Which company is conducting major trials for subarachnoid hemorrhage drugs?
  • Which companies/institutions are involved in subarachnoid hemorrhage collaborations aimed at providing enhanced therapeutic alternatives for patients?
  • What are the geographies covered for clinical trials in subarachnoid hemorrhage?
Related Reports

Global Intracranial Aneurysm Market

Global Clinical Trials Market

Table of Contents

200 Pages
1 Preface
1.1 Introduction
1.2 Objectives of the Study
1.3 Research Methodology & Assumptions
2 Executive Summary
3 Overview of Subarachnoid Hemorrhage
3.1 Signs and Symptoms
3.2 Causes
3.3 Risk Factors
3.4 Diagnosis
3.5 Treatment
4 Patient Profile: Subarachnoid Hemorrhage
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Subarachnoid Hemorrhage: Epidemiology Snapshot
5.1 Subarachnoid Hemorrhage Incidence by Key Markets
5.2 Subarachnoid Hemorrhage – Patients Seeking Treatment in Key Markets
6 Subarachnoid Hemorrhage: Market Dynamics
6.1 Market Drivers and Constraints
6.2 SWOT Analysis
7 Subarachnoid Hemorrhage: Key Facts Covered
7.1 Top Countries Contributing to Clinical Trials in Asia-Pacific
7.2 Top Countries Contributing to Clinical Trials in Europe
7.3 Top Countries Contributing to Clinical Trials in North America
7.4 Top Countries Contributing to Clinical Trials in Other Regions
8 Subarachnoid Hemorrhage, Drug Pipeline Assessment
8.1 Assessment by Treatment Type
8.2 Assessment by Route of Administration
8.3 Assessment by Drug Class
9 EMR Drug Pipeline Comparative Analysis
9.1 List of Subarachnoid Hemorrhage Pipeline Drugs
9.1.1 By Company
9.1.2 By Phase
9.1.3 By Indication
9.1.4 By Trial Status
9.1.5 By Funder Type
9.2 EMR Attribute Scoring Analysis of Pipeline Drugs (Top Drugs)
10 Subarachnoid Hemorrhage Drug Pipeline - Late-Stage Products (Phase III and IV) (Top Drugs)
10.1 Comparative Analysis for Late-Stage Drugs
10.1.1 Study Type
10.1.2 Recruitment Status
10.1.3 Company
10.1.4 Funder Type
10.2 Product Level Analysis*
10.2.1 Drug: Telavancin Injection
10.2.1.1 Product Description
10.2.1.2 Trial ID
10.2.1.3 Sponsor Name
10.2.1.4 Study Type
10.2.1.5 Drug Class
10.2.1.6 Eligibility Criteria
10.2.1.7 Study Record Dates
10.2.1.7.1 First Submitted
10.2.1.7.2 First Posted
10.2.1.7.3 Last Update Posted
10.2.1.7.4 Last Verified
10.2.1.8 Indication
10.2.1.9 Study Design
10.2.1.10 Recruitment Status
10.2.1.11 Enrollment (Estimated)
10.2.1.12 Location Countries
10.2.1.13 Recent Results
10.2.2 Other Drugs
11 Subarachnoid Hemorrhage Drug Pipeline - Mid-Stage Products (Phase II) (Top Drugs)
11.1 Comparative Analysis for Mid-Stage Drugs
11.1.1 Study Type
11.1.2 Recruitment Status
11.1.3 Company
11.1.4 Funder Type
11.2 Product Level Analysis*
11.2.1 Drug: Levosimenda
11.2.1.1 Product Description
11.2.1.2 Trial ID
11.2.1.3 Sponsor Name
11.2.1.4 Study Type
11.2.1.5 Drug Class
11.2.1.6 Eligibility Criteria
11.2.1.7 Study Record Dates
11.2.1.7.1 First Submitted
11.2.1.7.2 First Posted
11.2.1.7.3 Last Update Posted
11.2.1.7.4 Last Verified
11.2.1.8 Indication
11.2.1.9 Study Design
11.2.1.10 Recruitment Status
11.2.1.11 Enrollment (Estimated)
11.2.1.12 Location Countries
11.2.1.13 Recent Results
11.2.2 Other Drugs
12 Subarachnoid Hemorrhage Drug Pipeline - Early-Stage Products (Phase I) (Top Drugs)
12.1 Comparative Analysis for Early-Stage Drugs
12.1.1 Study Type
12.1.2 Recruitment Status
12.1.3 Company
12.1.4 Funder Type
12.2 Product Level Analysis*
12.2.1 Drug: Long Term Prophylactic Antibiotics (Nafcillin or Doxycycline)
12.2.1.1 Product Description
12.2.1.2 Trial ID
12.2.1.3 Sponsor Name
12.2.1.4 Study Type
12.2.1.5 Drug Class
12.2.1.6 Eligibility Criteria
12.2.1.7 Study Record Dates
12.2.1.7.1 First Submitted
12.2.1.7.2 First Posted
12.2.1.7.3 Last Update Posted
12.2.1.7.4 Last Verified
12.2.1.8 Indication
12.2.1.9 Study Design
12.2.1.10 Recruitment Status
12.2.1.11 Enrollment (Estimated)
12.2.1.12 Location Countries
12.2.2 Other Drugs
13 Subarachnoid Hemorrhage Drug Pipeline - Preclinical and Discovery Stage Products (Top Drugs)
13.1 Comparative Analysis for Preclinical and Discovery Stage Drugs
13.1.1 Study Type
13.1.2 Recruitment Status
13.1.3 Company
13.1.4 Funder Type
13.2 Product Level Analysis*
13.2.1 Drug 1
13.2.1.1 Product Description
13.2.1.2 Trial ID
13.2.1.3 Sponsor Name
13.2.1.4 Study Type
13.2.1.5 Drug Class
13.2.1.6 Eligibility Criteria
13.2.1.7 Study Record Dates
13.2.1.7.1 First Submitted
13.2.1.7.2 First Posted
13.2.1.7.3 Last Update Posted
13.2.1.7.4 Last Verified
13.2.1.8 Indication
13.2.1.9 Study Design
13.2.1.10 Recruitment Status
13.2.1.11 Enrollment (Estimated)
13.2.1.12 Location Countries
13.2.2 Other Drugs
14 Subarachnoid Hemorrhage, Key Drug Pipeline Companies
14.1 Acasti Pharma Inc.
14.1.1 Company Snapshot
14.1.2 Pipeline Product Portfolio
14.1.3 Financial Analysis
14.1.4 Recent News and Developments
14.2 Cumberland Pharmaceuticals
14.2.1 Company Snapshot
14.2.2 Pipeline Product Portfolio
14.2.3 Financial Analysis
14.2.4 Recent News and Developments
14.3 Takeda Pharmaceuticals
14.3.1 Company Snapshot
14.3.2 Pipeline Product Portfolio
14.3.3 Financial Analysis
14.3.4 Recent News and Developments
14.4 Orion Corporation
14.4.1 Company Snapshot
14.4.2 Pipeline Product Portfolio
14.4.3 Financial Analysis
14.4.4 Recent News and Developments
14.5 Arbor Pharmaceuticals
14.5.1 Company Snapshot
14.5.2 Pipeline Product Portfolio
14.5.3 Financial Analysis
14.5.4 Recent News and Developments
14.6 Edge Therapeutics Inc.
14.6.1 Company Snapshot
14.6.2 Pipeline Product Portfolio
14.6.3 Financial Analysis
14.6.4 Recent News and Developments
15 Regulatory Framework for Drug Approval, By Region
16 Terminated or Suspended Pipeline Products

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us